TP53 and neoplasm: The presence of wild-type TP53 in cell lines was associated with in vitro growth inhibition in response to many chemotherapeutic agents, including DNA/RNA antimetabolites, alkylating agents and topoisomerase I and II inhibitors.9–11 Although TP53 is a tumour-suppressor gene, TP53 mutations can be either ‘gain of function' (GOF) mutations or ‘loss of function' (LOF) mutations.